



Cochrane Database of Systematic Reviews
 
Medical abortion oered in pharmacy versus clinic-based settings
(Protocol)
 
  Rodriguez MI, Henderson J, Gartoulla P, Garner P, Edelman A  
  Rodriguez MI, Henderson J, Gartoulla P, Garner P, Edelman A. 
Medical abortion o%ered in pharmacy versus clinic-based settings. 




Medical abortion oered in pharmacy versus clinic-based settings (Protocol)
 








Cochrane Database of Systematic Reviews









CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 8
DECLARATIONS OF INTEREST..................................................................................................................................................................... 8
SOURCES OF SUPPORT............................................................................................................................................................................... 8
NOTES........................................................................................................................................................................................................... 8
Medical abortion oered in pharmacy versus clinic-based settings (Protocol)









Cochrane Database of Systematic Reviews
[Intervention Protocol]
Medical abortion oered in pharmacy versus clinic-based settings
Maria I Rodriguez1, Jillian Henderson1, Pragya Gartoulla2, Paul Garner3, Alison Edelman1
1Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon, USA. 2Melbourne School of
Population and Global Health, University of Melbourne, Melbourne, Australia. 3Department of Clinical Sciences, Liverpool School of
Tropical Medicine, Liverpool, UK
Contact address: Maria I Rodriguez, Department of Obstetrics and Gynecology, Oregon Health and Science University, 3181 SW Sam
Jackson Park Road, UHN 50, Portland, Oregon, 97239, USA. rodrigma@ohsu.edu.
Editorial group: Cochrane Fertility Regulation Group.
Publication status and date: New, published in Issue 3, 2020.
Citation:  Rodriguez MI, Henderson J, Gartoulla P, Garner P, Edelman A. Medical abortion o%ered in pharmacy versus clinic-based
settings. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013566. DOI: 10.1002/14651858.CD013566.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the safety and e%icacy of medical abortion o%ered in pharmacy settings with clinic-based medical abortion.
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B A C K G R O U N D
Description of the condition
Unsafe abortion remains a significant threat to women’s lives and
health (Alkema 2016; Ganatra 2017; WHO 2016). The World Health
Organization (WHO) estimates that globally, 25 million unsafe
abortions occur every year. Unsafe abortion is the fiHh leading
cause of maternal mortality (Ganatra 2017).
Improving access to medical abortion is one strategy to reduce
unsafe abortion, particularly where trained surgical abortion
providers are limited. A growing proportion of abortions globally
are medical abortions (Jones 2017; United Nations Population
Fund 1994). The WHO has published guidance on e%ective regimens
for medical abortion, and interventions such as laboratory testing
or ultrasound are not universally required (WHO 2012).
Description of the intervention
Medical abortion is o%ered routinely in clinics and hospitals, but
could be o%ered in other settings such as pharmacies. The safety
and e%ectiveness of medical abortion provision through non-
physician clinicians, such as nurses and auxiliary nurse midwives
has been established (Olavarrieta 2015; Warriner 2011). Expanding
access to medical abortion through pharmacies is a potential
strategy to promote safe abortion care. In many countries,
pharmacies are a first and common point of access for women
seeking reproductive health information and services, including
abortion (Billings 2009; Footman 2018; Sneeringer 2012).
The safety and e%ectiveness of services obtained from pharmacies
relative to other clinical sites are not known. It is possible
that lower-quality information or products may be supplied in
pharmacies than in clinics, increasing the rates of incomplete
abortion or other complications.
Currently, medical abortion is usually o%ered in clinics and
hospitals. Research to date has shown that a medical abortion
regimen combining mifepristone with misoprostol is most e%ective;
however, there is some variation in recommendations related to
dose, timing and route of administration of the two drugs. A large
body of evidence, and recommendations by the WHO, supports
the e%icacy of a 200 mg dose of mifepristone followed by 800
mcg of misoprostol in pregnancies up to 63 days’ gestational age
(Raymond 2013; WHO 2014).  Recent data support extending its
use up to 70 days’ gestation (Abbas 2015).  These protocols are
highly e%ective and safe, with unsuccessful abortion resulting in
approximately 2% to 5% of cases (Kulier 2011; Raymond 2013). In
settings where mifepristone is not available, medical abortion is
carried out using only misoprostol.
The recommended misoprostol regimen is 800 μg administered
vaginally or sublingually (under the tongue), and repeated at
intervals of no less than three hours but no more than 12 hours,
for up to three doses. This regimen is 75% to 90% e%ective in
completing abortions up to 84 days’ gestation. Gestational age is
known to a%ect the e%icacy of all regimens, with decreasing e%icacy
aHer nine weeks’ gestation (Winiko% 2008), which is why regimens
for these gestations recommend repeating misoprostol doses. This
review will focus on medical abortion provided with mifepristone
and misoprostol or misoprostol-alone regimens.
How the intervention might work
Pharmacies may be able to improve access to safe and
e%ective medical abortion care. Pharmacies are utilized for their
convenience, anonymity, and low cost as compared to a traditional
health clinic or hospital (Ahmed 2007; Footman 2018). They may
improve access for women with limited autonomy, or those
living in rural areas, where clinical access is remote (Rocca
2018).  Trained pharmacists and pharmacy workers deliver care
related to a range of reproductive health conditions, including
sexually transmitted infections, emergency contraception and
provision of other family planning methods, like birth control pills
(Sneeringer 2012). Pharmacists have been successful in delivering
reproductive health care because of their ability to provide quick
access to necessary information, medications, and referrals, while
maintaining confidentiality (Gonsalves 2017).
It is not known how pharmacist provision of medical abortion
may impact important safety or e%icacy outcomes, as compared
with the clinical setting. Pharmacists may have less training than
clinicians in accurate usage of the medications to achieve a
complete abortion. It is possible that pharmacists working in retail
settings would have less time to counsel women than clinicians on
known side e%ects or possible complications, increasing the risk
of infection or heavy bleeding leading to hospital attendance. It is
important to explore how the setting of care provision (pharmacy
versus clinic) impacts key safety and e%icacy outcomes, including
complete abortion, blood transfusion or hospital admission.
Why it is important to do this review
Globally, pharmacies play a key role in the formal or informal
distribution of information or medications for abortion (Billings
2009; Footman 2018; Lara 2011; Reiss 2016; Reiss 2017; Sneeringer
2012; Tamang 2015; Tamang 2018).  Existing data on the safety
and e%icacy of this practice is limited, and has demonstrated
mixed results on the accuracy of information and medical
abortion regimens provided by pharmacy workers (Ahmed 2007;
Billings 2009; Footman 2018; Reiss 2016; Rocca 2018).  Safe
and e%ective abortion can reduce complications associated with
unsafe abortion, and maternal mortality (Ganatra 2017; WHO
2012).  Pharmacy provision of medical abortion may have the
potential to reduce morbidity associated with unsafe abortion.
However, evidence is needed to establish whether the safety and
e%ectiveness of care is equivalent to that o%ered in a clinic.
O B J E C T I V E S
To compare the safety and e%icacy of medical abortion o%ered in
pharmacy settings with clinic-based medical abortion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will seek studies that compare women receiving the same
regimen of medical abortion or postabortion care in either a clinic
or pharmacy setting. Studies published in any language employing
the following designs will be included: randomized trials (clustered
or individually randomized); quasi-experimental designs, such
as non-randomized or stepped-wedge design experiments; and
cohort studies with a control group.
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We will also seek prospective cohort studies that report on
outcomes, and compare these between the clinic and pharmacy
setting. For safe abortion, programs will incorporate the woman’s
right to choose her preferred mode of abortion; in other settings,
studies may be carried out in countries where abortion access
is restricted, and an RCT not possible. Observational studies will
reflect programmatic implementation and will detect serious and
uncommon harms.
Types of participants
Pregnant women of any age, seeking abortion care in pharmacies
or traditional clinics, are eligible for inclusion.
Types of interventions
The intervention is pharmacy delivery of any component of
medical abortion services.  This includes dispensing medical
abortion medications. Only studies that provided medical abortion
using mifepristone and misoprostol or misoprostol alone will be
included. The only administration for mifepristone is oral. Di%erent
administration routes and dosing regimens for misoprostol may be
used, and we will include studies using any route (oral, sublingual,
buccal, and vaginal) or regimen (e.g., repeat dosing). We will
consider all types of providers in the intervention group (including
pharmacist, pharmacy worker) and in the comparison group
(physician, nurse midwife, auxiliary nurse midwife, and nurse). We
are not considering surgical abortion outcomes in this review.
Comparison
Women receiving medical abortion in clinical health care settings
compared with pharmacy settings.
Types of outcome measures
Primary outcomes
• Complete abortion defined as completion of abortion within 30
days of taking the first medication, and not requiring surgical
intervention for completion
• Blood transfusion within 30 days of medical abortion
• Uterine or systemic infection within 30 days of medical abortion
Secondary outcomes
• Hospital admission for an abortion related event
• Quality of medical abortion care (Any study reported measures
of technical or interpersonal quality of care will be considered
- priority will be placed on synthesis of validated measures if
available; Darney 2018; Darney  2019)
• Additional surgical interventions (besides uterine aspiration)
Search methods for identification of studies
The Fertility Regulation Group Information Specialist will conduct a
search for all published, unpublished, and ongoing studies, without
restrictions on language or publication status. The search strategies
for each database will be modelled on the search strategy designed
for MEDLINE ALL (Ovid) (Epub Ahead of Print, In-Process & Other
Non-Indexed Citations and Daily) in Appendix 1. We will check
the bibliographies of included studies and any relevant systematic
reviews identified for further references to relevant studies. We will
contact experts and organizations in the field to obtain additional
information on relevant studies. We may contact original authors
for clarification and further data if study reports are unclear. We
will consider adverse e%ects described in included studies only. We
will not restrict by language, and will arrange to translate studies
published in languages other than English.
Electronic searches
We will search the following databases from their inception.
• EBM Reviews Ovid - Cochrane Central Register of Controlled
Trials
• MEDLINE Ovid (Epub Ahead of Print, In-Process & Other Non-





• Global Health Ovid
• Scopus
We will search the following trials registries.
• The World Health Organization International Clinical Trials
Registry Platform www.who.int/trialsearch
• ClinicalTrials.gov www.clinicaltrials.gov
Please see Appendix 1 for the proposed search strategy.
Searching other resources
We will search the following grey literature sites.
• Guttmacher Institute https://www.guttmacher.org/united-
states/abortion
• International Planned Parenthood Federation https://
www.ippf.org/
• Ibis Reproductive Health https://ibisreproductivehealth.org/
• Women on Waves https://www.womenonwaves.org/
• Marie Stopes International https://www.mariestopes.org/
• Population Council https://www.popcouncil.org/
• Population Services International https://www.psi.org/
• Ipas https://www.ipas.org/
• Google Scholar https://scholar.google.com/
Data collection and analysis
Selection of studies
We will download all titles and abstracts retrieved by electronic
searching to a reference management database, and remove
duplicates (Covidence ). Two reviewers will independently screen
titles and abstracts for inclusion. We will retrieve the full-text
study reports or publications, and two reviewers will independently
screen the full text, identify studies for inclusion, and identify and
record reasons for exclusion of the ineligible studies. We will resolve
any disagreement through discussion.
We will list studies that initially appeared to meet the inclusion
criteria, but that we later excluded, in the 'Characteristics of
excluded studies' table. We will collate multiple reports of the same
study, so that each study rather than each report is the unit of
interest in the review. We will also provide any information we can
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obtain about ongoing studies. We will record the selection process
in su%icient detail to complete a PRISMA flow diagram (Liberati
2009).
Data extraction and management
Two review authors will independently screen and extract data
from eligible studies, using a data extraction form designed
and pilot-tested by the review authors. We will resolve any
disagreements by discussion. Study design and participant
characteristics and outcome data will be described in evidence
tables. The drugs used, dose, and route of administration will be
recorded, as well as each study’s inclusion and exclusion criteria.
Assessment of risk of bias in included studies
Two authors will independently assess any included trials for
risk of bias using the Cochrane Risk of Bias Assessment tool
(Higgins 2019). We will specifically assess: selection bias (random
sequence generation and allocation concealment); performance
bias (blinding of participants and personnel); detection bias
(blinding of outcome assessors); attrition bias (incomplete
outcome data); reporting bias (selective reporting); and other
biases. We will pay particular attention to whether there was
participant or investigator selection bias towards location of
treatment. We will rate studies as low risk, high risk, or unclear risk
using the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019).
For NRS, we will similarly conduct dual, independent assessment
of risk of bias using the ROBINS-I tool (Sterne 2016). The domains
assessed with this tool are bias at the pre-, at-, and post-
intervention stages of the study. Specifically, the domains are:
pre-intervention bias due to confounding (prognostic variables
predict outcome of interest) and selection (inclusion or exclusion
of participants related to outcome of interest); at-intervention
information bias (misclassification of intervention status); and,
post-intervention confounding, selection bias, information bias,
and reporting bias. Use of the ROBINS-I tool will facilitate
assessment of risk of bias for each domain. For the comparisons
we will evaluate, we expect selection bias and confounding pre-
and post-intervention are likely to be of particular importance. The
research and clinical expertise of study team members will ensure
thorough characterization of risk of bias. We will analyze high-
quality and low-quality studies in combination and separately to
minimize risk of bias. Gestational age is known to be an important
confounder in medical abortion (Kahn 2000).  The presence of
appropriate adjustment for gestational age will be examined in
evaluating the risk of bias.
We will use the GRADE approach to assess the quality of the body
of evidence used in the meta-analysis for study outcomes. For the
synthesis of outcomes drawn from NRS, the evidence will begin
with a rating of low certainty given the risks of bias from selection
and confounding inherent in NRS designs. We will be using the
ROBINS-I tool, however, and may upgrade the certainty level if
e%ects are particularly strong and the risks of confounding and
selection are judged to be particularly well-mitigated.
Measures of treatment eect
For dichotomous data (e.g. complete abortion, yes/no), we will use
the number of events in the clinic and pharmacy groups of each
study to calculate relative risks (RR) or Mantel-Haenszel odds ratios
(ORs), depending on the most commonly reported e%ect estimates
across the body of evidence. We will extract reported means and
standard deviations for continuous outcomes, either as reported in
the primary study or calculated from reported estimates of variance
to calculate mean di%erence with 95% confidence intervals. For
NRS, we will prioritize synthesis of study reported adjusted e%ect
estimates and will select the estimate judged to most minimize the
risk of bias due to confounding and selection. We will present 95%
confidence intervals as the measure of precision for all outcomes
estimates. Where data to calculate ORs, RRs or mean di%erences
are not available, we will use the most detailed numerical data
available to facilitate synthesis across included studies (e.g., test
statistics, P values). We will assess whether the estimates we
calculate in the review for each individual study are consistent with
the available estimates of e%ects reported in the study publications.
Unit of analysis issues
The primary unit of analysis will be per woman randomized
for RCTs and per woman who undergoes medical abortion
(classified as pharmacy or clinic-administered) for NRS. For cluster-
RCTs included in the review, we will report trial outcome data
adjusted for the hierarchical study design (i.e., within cluster
correlations among observations that lead to underestimation of
standard errors) whenever available and will use these estimates
in meta-analysis. Studies that do not report data with appropriate
adjustments for study design will be described in tables with
the potential for overestimating e%ect precision noted. For
meta-analysis of unadjusted cluster-RCT outcomes, intracluster
correlation coe%icients (ICC) based on observations from similar
studies will be used to estimate adjustments to the standard errors
following recommended procedures (Higgins 2019).
Dealing with missing data
We will analyze the data on an intention-to-treat basis as far as
possible. We will reach out to authors to obtain missing data. Where
these are unobtainable, we will analyze only the available data.
Assessment of heterogeneity
We will synthesize e%ectiveness in a meta-analysis using a random-
e%ects model, to produce pooled OR, RR, or mean di%erence e%ect
estimates with 95% confidence interval (CI). We are selecting this
model a priori to incorporate the e%ect of trial heterogeneity among
prospective studies from di%erent settings. We will assess statistical
heterogeneity using the Chi2 tests and I2 statistics.   We will
use recommendations in the Cochrane Handbook for Systematic
Reviews of Interventions to interpret the I2 values, and consider
a score of over 50% to indicate the possibility of substantial
heterogeneity (Higgins 2019).
Assessment of reporting biases
Considering the di%iculties in detecting and correcting for
publication bias and other reporting biases, we will aim to minimize
their potential impact by ensuring a comprehensive search for
eligible studies, and by being alert for duplication of data. If there
are at least 10 studies available for pooled analysis, we will use a
funnel plot to explore the possibility of small-study e%ects.
Data synthesis
If we judge the studies to be su%iciently similar with respect to study
participants, interventions, comparators, and outcomes, e%ects are
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relatively consistent, and statistical heterogeneity is no greater
than moderate (< 60%) we will conduct meta-analysis using Review
Manager 5.3 (Review Manger 2014). We will conduct quantitative
synthesis separately for randomized and NRS evidence. We will
combine data using the DerSimonian and Laird random-e%ects
model (DerSimonian 1986). These summary e%ects are grounded
in the assumption that the pooled estimate is an average e%ect
from an underlying distribution of true e%ects. Such a model
is appropriate for this body of evidence given the expected
heterogeneity of populations and intervention characteristics. For
meta-analysis of NRS, we will seek to pool adjusted e%ect estimates
using the generic inverse variance approach. If only unadjusted
estimates are available, they will be pooled separately from
adjusted e%ects. 
We will present forest plots showing the pooled estimates and
95% CI for each outcome suitable for meta-analysis. Descriptive
forest plots for evidence on primary outcomes that are not judged
appropriate to pool will also be presented, with a narrative
synthesis also provided for outcomes lacking adequate data
to combine across studies. This synthesis will consider the
consequences of possible incomplete reporting on the outcomes of
interest, and the strengths and limitations of available studies for
evaluating the review questions.
Subgroup analysis and investigation of heterogeneity
There may be di%erences in the e%ectiveness and safety of
pharmacy provided medical abortion depending on several factors,
including the following determined a priori to be important
to evaluate in subgroup comparisons: Type of health workers
providing abortion care in pharmacies (physicians, midwives,
nurses, pharmacists, medical assistants), client characteristics
(e.g., gestation < 9 weeks, parity), abortion regimen (e.g., dosage,
administration route), and the human development index category
of the country where the study was conducted.
We will estimate stratified forest plots with pooled subgroup e%ect
estimates and will conduct statistical tests for interaction using
meta-regression. If we detect substantial statistical heterogeneity
unexplained by these factors, we will explore additional possible
explanations in post hoc subgroup analyses derived from the
available evidence and its synthesis. When interpreting the results,
we will describe the statistical heterogeneity, potential explanatory
factors, and inconsistency in the direction of e%ects across studies
that contribute to the pooled e%ect.
Sensitivity analysis
As needed, to more fully understand and evaluate the body of
evidence, we will conduct sensitivity analyses to assess the e%ect
of risk of bias, removing included studies rated high risk of bias for
the primary outcomes.
Summary of findings and assessment of the certainty of the
evidence
We will use GRADEpro and Cochrane methods to prepare a
‘Summary of findings’ table (GRADEpro GDT;  Higgins 2019).  The
table will evaluate the overall quality of the body of evidence for the
review outcomes on e%ectiveness and safety of medical abortion
provided in pharmacy settings. We will use the GRADE criteria (e.g.,
risk of bias, consistency of e%ect, imprecision, indirectness, and
publication bias) to assess the quality of the evidence (Guyatt 2008).
As noted above, the NRS evidence will be initially rated as low
quality and the rating will be further refined based on the ROBINS-
I risk of bias assessments.
Two review authors will work independently to judge the evidence
quality (e.g., high, moderate, low, or very low) and will resolve any
disagreements by discussion. The reviewers will justify, document,
and incorporate their judgments into reporting the results of each
outcome.
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A P P E N D I C E S
Appendix 1. Model search strategy
Ovid MEDLINE(R) ALL 1946 to 7 January 2020
Date searched: January 8, 2020
1 Abortion, Induced/ or Abortion, Eugenic/ or Abortion, Legal/ or Abortion, Therapeutic/ or Abortion, Incomplete/ or Abortion Applicants/
or Abortion, Criminal/ or Abortifacient Agents/ or Abortifacient Agents, Nonsteroidal/ or Abortifacient Agents, Steroidal/ or Menstruation-
Inducing Agents/ (42278)
2 (abortifacient* or abortion* or (menstrua* adj3 regulat*) or pre-abortion or preabortion or post-abortion or postabortion or post-
abortum or postabortum or feticid* or foeticid* or ((medical* or medication or medicin* or trimester* or gestation* or pregnan*) adj5 (post-
terminat* or postterminat* or pre-terminat* or preterminat* or terminat*))).tw,kf. (72951)
3 Mifepristone/ or Misoprostol/ (9271)
4 (Mifepristone or Misoprostol or Abo-pill or Colestone or Cytotec or Elmif or Epostane or Fenprostalene or GyMiso or Korlym or Medabon
or Mefeprin or Mefipil or Mifebort or Mifegest or Mifegyne or Mifeprex or Miferiv or MiHy or Mtpill or Nalador or RU-38486 or RU38486 or
RU-486 or RU486 or T-Pill or Termipil).tw,kf. (11441)
5 or/1-4 (95108)
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6 Pharmacies/ or Pharmacists/ or Pharmaceutical Services/ or Pharmacy Technicians/ or Community Pharmacy Services/ (28684)
7 (apothecar* or chemist* or dispens* or druggist* or drugstore* or pharmacy or pharmacies or pharmacist* or OTC or over-the-counter
or ((drug or medicine) adj4 (retail* or seller* or shop* or store* or vendor*))).ti,ab,kf. (281747)
8 or/6-7 (287093)
9 and/5,8 (650)
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N O T E S
This protocol is based on standard text and guidance provided by the Cochrane E%ective Practice and Organisation of Care (EPOC).
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